TissueLabs has closed a pre-seed round of $800,000 led by Mergus Ventures, with notable contributions from MIT Angels, among other funds and private investors. Concurrently, the company proudly unveils its state-of-the-art biofabrication hub in Bellinzona, advancing its mission to revolutionize healthcare through tissue engineering..

TissueLabs完成了由Mergus Ventures牵头的一轮80万美元的种子期前投资，麻省理工学院天使基金以及其他基金和私人投资者做出了显著贡献。与此同时，该公司骄傲地在贝林佐纳推出了其最先进的生物制造中心，推进了其通过组织工程彻底改变医疗保健的使命。。

The investment will expedite TissueLabs' research and development initiatives, particularly enhancing its proprietary technology platforms, expanding its team, and establishing strategic partnerships within the biotechnology sector. Importantly, part of the funds has been specifically allocated for setting up the new hub in Bellinzona, highlighting the company's commitment to fostering innovation in an emerging biotech cluster.

这项投资将加快TissueLabs的研发计划，特别是增强其专有技术平台，扩大其团队，并在生物技术领域建立战略伙伴关系。重要的是，部分资金专门用于在贝林佐纳建立新的中心，突显了该公司致力于促进新兴生物技术集群的创新。

TissueLab’s mission is to produce synthetic tissues and organs for therapeutic applications. Its product portfolio includes advanced 3D bioprinters, tissue-specific biomaterials, and specialized software..

TissueLab的使命是生产用于治疗应用的合成组织和器官。其产品组合包括先进的3D生物打印机、组织特异性生物材料和专业软件。。

TissueLabs' new facilities, located in the Gallera building at the heart of Bellinzona, comprise two independent state-of-the-art laboratories for production and research, alongside modern offices and meeting spaces. Dr. Gabriel Liguori, CEO and Founder of TissueLabs, expressed enthusiasm about this dual announcement: 'We are immensely grateful for the trust placed in us by Mergus Ventures, MIT Angels, and all our investors.

TissueLabs的新设施位于贝林佐纳市中心的Gallera大楼，包括两个独立的最先进的生产和研究实验室，以及现代化的办公室和会议空间。TissueLabs首席执行官兼创始人加布里埃尔·利古里（GabrielLiguori）博士对这一双重宣布表示了热情：“我们非常感谢Mergus Ventures、MIT Angels和所有投资者对我们的信任。

This investment, alongside our new facilities in Bellinzona, represents a significant leap towards achieving our vision.'.

这项投资，加上我们在贝林佐纳的新设施，代表着实现我们愿景的重大飞跃。”。

The Bellinzona hub will play a crucial role in scaling up the production of TissueLabs' innovative products, such as their 3D bioprinters and tissue-specific biomaterials, and the development of innovative solutions aimed at clinical applications. Dr. Tácia Liguori, CSO at TissueLabs, shared her excitement: 'Our shiny new labs aren't just for dreaming about what's next; they're where we roll up our sleeves and actually build the future.

贝林佐纳中心将在扩大TissueLabs创新产品（如3D生物打印机和组织特异性生物材料）的生产以及开发针对临床应用的创新解决方案方面发挥关键作用。TissueLabs的CSO塔西亚·利古里博士分享了她的兴奋：“我们闪亮的新实验室不仅仅是为了梦想下一步会发生什么；他们是我们卷起袖子，真正建设未来的地方。

The chance to speed up our work on new treatments has never felt more real.'.

加速我们新疗法工作的机会从未像现在这样真实。”。

(Press release / SK)

（新闻稿/SK）

0Comments

0注意事项

Back to all news

返回所有新闻

Please login

请登录

or sign up

或注册

to comment.

发表评论。

Commenting guidelines

评论指南

Send

发送